Evaluation of AR, AR-V7, and p160 family as biomarkers for prostate cancer: insights into the clinical significance and disease progression

Imagem de Miniatura
Arquivos
art_PIMENTA_Evaluation_of_AR_ARV7_and_p160_family_as_2024.PDF (1.42 MB)
Citações na Scopus
0
Tipo de produção
article
Data de publicação
2024
Editora
SPRINGER
DOI
Indexadores
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Métricas da Revista
JCR
SJR
Autores
MALULF, Feres Camargo
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, v.150, n.2, article ID 70, 13p, 2024
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Purpose To assess the role of the p160 family, AR, and AR-V7 in different initial presentations of prostate cancer and their association with clinical endpoints related to tumor progression. Methods The study sample comprises 155 patients who underwent radical prostatectomy and 11 healthy peripheral zone biopsies as the control group. Gene expression was quantified by qPCR from the tissue specimens. The statistical analysis investigated correlations between gene expression levels, associations with disease presence, and clinicopathological features. Additionally, ROC curves were applied for distinct PCa presentations, and time-to-event analysis was used for clinical endpoints. Results The AR-V7 diagnostic performance for any PCa yielded an AUC of 0.77 (p < 0.05). For locally advanced PCa, the AR-V7 AUC was 0.65 (p < 0.05). Moreover, the metastasis group had a higher expression of SRC-1 than the non-metastatic group (p < 0.05), showing a shorter time to metastasis in the over-expressed group (p = 0.005). Patients with disease recurrence had super-expression of AR levels (p < 0.0005), with a shorter time-to-recurrence in the super-expression group (p < 0.0001). Conclusion Upregulation of SRC-1 indicates a higher risk of progression to metastatic disease in a shorter period, which warrants further research to be applied as a clinical tool. Additionally, AR may be used as a predictor for PCa recurrence. Furthermore, AR-V7 may be helpful as a diagnostic tool for PCa and locally advanced cancer, comparable with other investigated tools.
Palavras-chave
Prostate cancer, Androgen receptor, p160, Biomarkers
URI
https://observatorio.fm.usp.br/handle/OPI/58730
Referências
  1. Agoulnik IU, 2006, CANCER RES, V66, P10594, DOI 10.1158/0008-5472.CAN-06-1023
  2. Agoulnik IU, 2005, CANCER RES, V65, P7959, DOI 10.1158/0008-5472.CAN-04-3541
  3. Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815
  4. Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965
  5. Assikis VJ, 2004, SEMIN ONCOL, V31, P26, DOI 10.1053/j.seminoncol.2004.02.008
  6. Attar RM, 2009, CLIN CANCER RES, V15, P3251, DOI 10.1158/1078-0432.CCR-08-1171
  7. Aurilio G, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9122653
  8. Bevan CL, 1999, MOL CELL BIOL, V19, P8383
  9. Chang AJ, 2014, NAT REV CLIN ONCOL, V11, P308, DOI 10.1038/nrclinonc.2014.68
  10. Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4
  11. Chung ACK, 2007, CANCER RES, V67, P5965, DOI 10.1158/0008-5472.CAN-06-3168
  12. Culig Z, 2004, J STEROID BIOCHEM, V92, P265, DOI 10.1016/j.jsbmb.2004.10.003
  13. Culig Z, 2016, J CELL PHYSIOL, V231, P270, DOI 10.1002/jcp.25099
  14. Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343
  15. dos Santos VG, 2022, UROLOGIA J, V89, P451, DOI 10.1177/03915603211036628
  16. EAU Guidelines, 2022, EAU ANN C AMSTERDAM
  17. Ferraldeschi R, 2015, ONCOGENE, V34, P1745, DOI 10.1038/onc.2014.115
  18. Fujita K, 2019, WORLD J MENS HEALTH, V37, P288, DOI 10.5534/wjmh.180040
  19. Gregory CW, 2001, CANCER RES, V61, P4315
  20. Gulley James, 2002, Clin Prostate Cancer, V1, P51, DOI 10.3816/CGC.2002.n.007
  21. He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219
  22. Heinlein CA, 2002, ENDOCR REV, V23, P175, DOI 10.1210/er.23.2.175
  23. Hoang DT, 2017, ONCOTARGET, V8, P3724, DOI 10.18632/oncotarget.12554
  24. Holzbeierlein J, 2004, AM J PATHOL, V164, P217, DOI 10.1016/S0002-9440(10)63112-4
  25. Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764
  26. Karantanos T, 2013, ONCOGENE, V32, P5501, DOI 10.1038/onc.2013.206
  27. Kim J, 2004, J CELL BIOCHEM, V93, P233, DOI 10.1002/jcb.20228
  28. Kishimoto H, 2005, CARCINOGENESIS, V26, P1706, DOI 10.1093/carcin/bgi137
  29. Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479
  30. Linja MJ, 2004, CLIN CANCER RES, V10, P1032, DOI 10.1158/1078-0432.CCR-0990-3
  31. Liu XH, 2012, STAT MED, V31, P2676, DOI 10.1002/sim.4509
  32. Ma G, 2011, INT J BIOL SCI, V7, P664, DOI 10.7150/ijbs.7.664
  33. McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357
  34. Nakka M, 2013, INT J BIOCHEM CELL B, V45, P763, DOI 10.1016/j.biocel.2012.12.012
  35. Neupane S, 2021, CANCERS, V13, DOI 10.3390/cancers13030435
  36. Obinata D, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.581515
  37. ONATE SA, 1995, SCIENCE, V270, P1354
  38. Paller CJ, 2013, HEMATOL ONCOL CLIN N, V27, P1205, DOI 10.1016/j.hoc.2013.08.005
  39. Powell SM, 2004, ENDOCR-RELAT CANCER, V11, P117, DOI 10.1677/erc.0.0110117
  40. Sharifi N, 2013, ENDOCRINOLOGY, V154, P4010, DOI 10.1210/en.2013-1466
  41. Sharma P, 2016, FUTUR SCI OA, V2, DOI 10.4155/fso.15.72
  42. Shoag J, 2016, ASIAN J ANDROL, V18, P543, DOI 10.4103/1008-682X.178852
  43. Siadat F, 2015, PROSTATE, V75, P1277, DOI 10.1002/pros.23009
  44. Sippell W G, 1994, Cesk Pediatr, V49, P13
  45. Sobhani N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115515
  46. Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629
  47. Thiyagarajan T, 2022, P NATL ACAD SCI USA, V120, DOI 10.1073/pnas.2211832120
  48. Tien JCY, 2009, INT J BIOL SCI, V5, P256
  49. Tosoian JJ, 2016, NAT REV UROL, V13, P205, DOI 10.1038/nrurol.2016.45
  50. Uo T, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.580617
  51. Wang S, 2009, P NATL ACAD SCI USA, V106, P151, DOI 10.1073/pnas.0808703105
  52. Wolf AMD, 2010, CA-CANCER J CLIN, V60, P70, DOI 10.3322/caac.20066
  53. Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695
  54. Yusim I, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-76786-9
  55. Zhang AL, 2016, HORM CANCER-US, V7, P104, DOI 10.1007/s12672-016-0250-9
  56. Zhao ZW, 2019, CANCERS, V11, DOI 10.3390/cancers11101603
  57. Zhou XE, 2010, J BIOL CHEM, V285, P9161, DOI 10.1074/jbc.M109.085779

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCG
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/13
Artigos e Materiais de Revistas Científicas - LIM/26
Artigos e Materiais de Revistas Científicas - LIM/55
Artigos e Materiais de Revistas Científicas - ODS/03